pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR
ME Therapeutics
Marker Therapeutics
ME Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Vancouver, British Columbia, CA
- Founded
- 2018
- Employees
- 4
- Programs
- 13
- Drugs
- 10
- Patents
- 27
ME Therapeutics projects
13 ClinicalTrials.gov programs sponsored by ME Therapeutics.
ME Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
FRα peptide plus Adjuvant (GM-CSF)
Marker Therapeutics
Platinum Sensitive Ovarian Cancer
1 trial -
Low dose FRα vaccine
Marker Therapeutics
Breast Cancer
1 trial -
MT-401
Marker Therapeutics
Acute Myeloid Leukemia
1 trial -
TPIV200
Marker Therapeutics
Ovarian Cancer
1 trial -
HER-2/neu peptide vaccine
Marker Therapeutics
HER2-positive Breast Cancer
1 trial -
MT-401-OTS
Marker Therapeutics
Acute Myeloid Leukemia, in Relapse
1 trial -
MT-601
Marker Therapeutics
Non-Hodgkin Lymphoma, Adult
1 trial -
MT-601 dose 200 million cells
Marker Therapeutics
Pancreas Cancer
1 trial -
Mail-in Urine Test for EDCs
Marker Therapeutics
Endocrine Disrupting Chemicals
1 trial -
Urinary EDC metabolite testing
Marker Therapeutics
Obesity &Amp;Amp;Amp; Overweight
1 trial -
Urinary EDC metabolite testing
Marker Therapeutics
Environmental Exposure
1 trial -
blood sampling
Marker Therapeutics
Colorectal Cancer Screening
1 trial -
blood sampling
Marker Therapeutics
Screening for Colon Cancer
1 trial
Frequently asked questions
How many clinical projects does ME Therapeutics have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.